HALLE/SAALE, Germany, July 31, 2014 – Probiodrug AG (Probiodrug) announced today that Dr. Stephan Schilling, an expert consultant to the Company, will give an invited presentation […]
Probiodrug Presents Development Overview of PQ912, Probiodrug’s QC-Inhibitor for Alzheimer’s Disease
HALLE/SAALE, Germany, July 10, 2014 – Probiodrug AG (Probiodrug) announced that Prof. Hans-Ulrich Demuth, co-founder and consultant to the company, will give a talk detailing clinical […]
HALLE/SAALE, Germany, June 19, 2014 – Probiodrug AG (Probiodrug), today announced that Dr. Hendrik Liebers, Probiodrug’s chief financial officer, will present a corporate update at the […]
HALLE/SAALE, Germany, June 2, 2014 – Probiodrug AG (Probiodrug), today announced that the Company will participate in the second annual Asia Biotech Invest conference, to be […]
HALLE/SAALE, Germany, May 19, 2014 – Probiodrug AG (Probiodrug), today announced that Dr. Hendrik Liebers, chief financial officer of Probiodrug, will be presenting a corporate update […]
HALLE/SAALE, Germany, March 26th, 2014 – Probiodrug AG (Probiodrug), today announced that Dr. Hendrik Liebers, the Company’s chief financial officer, will provide an update of corporate, […]
HALLE/SAALE, Germany, February 7, 2014 – Probiodrug AG (Probiodrug), today announced that Dr Konrad Glund, the Company’s chief executive officer, will provide an update of corporate […]
HALLE/SAALE, Germany, January 10, 2014 – Probiodrug AG (Probiodrug), together with the VU University Medical Center (VUmc) Alzheimer Center in Amsterdam, have entered into a collaboration […]
HALLE/SAALE, Germany, January 3, 2014 – Probiodrug AG (Probiodrug) announced today the transfer of its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca (LSE: AZN, […]